ARIH2

Across TCGA pan-cancer cohorts, ARIH2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ARIH2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ARIH2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARIH2 expression acts as an unfavorable survival marker.

PDAC, CCRCC, and LUAD are the cancer types where ARIH2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.174	0.496	.016	11	view →
CCRCC	OS	Tertile	All	0.905	1.000	.018	9	view →
LUAD	DFS	Median	III,IV	0.432	0.925	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ARIH2–PDAC (DFS)

Open the PDAC breakdown →